AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23774876
Drug: Cobicistat-boosted elvitegravir
RxNorm normalized name: cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cobicistat-boosted elvitegravir (EVG/co; 150/150 mg QD) administered simultaneously or staggered (+12 hours) with famotidine or omeprazole
Trial: 23774876
Drug: Staggered antacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Staggered antacid administration by ≥2 hours
Trial: 15752122
Drug: PUVA-gel therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVA-gel therapy (aqueous 8-methoxypsoralen (8-MOP)-containing gel plus broadband UVA irradiation)
Trial: 15752122
Drug: PUVA-bath therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVA-bath therapy (8-MOP bath of the hands and/or feet plus broadband UVA)
Trial: 11812684
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural anesthesia (TEA) with ropivacaine 1% (4‐mL bolus, 3‐5 mL/h infusion), fentanyl (100‐microg bolus, 15‐25 microg/h infusion), and propofol infusion (6 mg x kg(‐1) x h(‐1))
Trial: 11812684
Drug: General Anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General Anesthesia with fentanyl (15 microg/kg) and propofol (5 mg x kg(‐1) x h(‐1)), followed by IV morphine patient‐controlled analgesia
Trial: 1836919
Drug: Recombinant DNA
RxNorm normalized name: Recombinant DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant DNA hepatitis B vaccine (10 micrograms) with DT and OPV
Trial: 1836919
Drug: Recombinant DNA
RxNorm normalized name: Recombinant DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant DNA hepatitis B vaccine (10 micrograms) with DT and OPV (Group III)
Trial: 1836919
Drug: Recombinant DNA
RxNorm normalized name: Recombinant DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant DNA hepatitis B vaccine (10 micrograms) with DT and OPV (Groups I and II)
Trial: 7222859
Drug: Intravenous tinofedrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tinofedrine (0.12 to 0.17 mg/kg body‐weight)
Trial: 30098134
Drug: Insulin-stimulated brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-stimulated brain glucose uptake (BGU) in obese participants
Trial: 30098134
Drug: Insulin-stimulated brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-stimulated brain glucose uptake (BGU) in obese participants post-bariatric surgery
Trial: 30098134
Drug: High insulin-stimulated
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High insulin-stimulated BGU at baseline
Trial: 30098134
Drug: Insulin-stimulated brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-stimulated brain glucose uptake (BGU) in all participants
Trial: 23751236
Drug: 1000mcg chromium/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mcg chromium/day (high dose)
Trial: 23751236
Drug: 600mcg chromium/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600mcg chromium/day (moderate dose)
Trial: 19090875
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil (3 doses)
Trial: 9062374
Drug: Antidepressants (sertraline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (sertraline and imipramine)
Trial: 3085552
Drug: Fentanyl 3
RxNorm normalized name: FENTANYL 37.5MCG/HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 3 micrograms/kg plus continuous intravenous nitroglycerin infusion 0.9 microgram X kg‐1 X min‐1 (group 3, n = 20)
Trial: 30182786
Drug: JNJ-42847922 (5-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-42847922 (5-60 mg orally once daily for 10 days)
Trial: 30182786
Drug: JNJ-42847922 (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-42847922 (doses >5 mg)
Trial: 30182786
Drug: JNJ-42847922 (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-42847922 (doses >10 mg)
Trial: 27154159
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg intravenous methylprednisolone
Trial: 22864179
Drug: Omeprazole 10mg
RxNorm normalized name: OMEPRAZOLE 10MG CAP,SA
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole 10mg daily
Trial: 22864179
Drug: Famotidine 20mg
RxNorm normalized name: FAMOTIDINE 20MG TAB
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Famotidine 20mg daily
Trial: 21260940
Drug: Oral intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral intake of oxibutinin
Trial: 21260940
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (intravesical electroneurostimulation and magnetophoresis)
Trial: 18832294
Drug: Ambrisentan 10
RxNorm normalized name: ambrisentan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan 10 mg alone
Trial: 18832294
Drug: Sildenafil 20
RxNorm normalized name: sildenafil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 20 mg 3 times daily after 7 days of ambrisentan 10 mg once daily
Trial: 15963399
Drug: High-dose furosemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose furosemide (500 to 1,000 mg) plus hypertonic saline solution (HSS) twice a day for four to six days
Trial: 15963399
Drug: High-dose furosemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose furosemide (500 to 1,000 mg) alone, twice a day for four to six days
Trial: 31969977
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (24 International Units once daily for 4 weeks)
Trial: 25701159
Drug: Standard parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard parenteral nutrition with glutamine supplementation (SPN + Gln)
Trial: 23798635
Drug: Standard parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard parenteral nutrition (SPN)
Trial: 19539361
Drug: Rivaroxaban (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (5-20 mg, once daily or twice daily)
Trial: 17292895
Drug: 600 IU
RxNorm normalized name: Vitamin E 4600 IU/5 ML Oral Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 IU of recombinant follicle-stimulating hormone (FSH) as the control group (group A)
Trial: 17292895
Drug: 600 IU
RxNorm normalized name: Vitamin E 4600 IU/5 ML Oral Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 IU of recombinant FSH plus daily supplementation with 75 IU of recombinant luteinizing hormone (group B)
Trial: 17292895
Drug: 600 IU
RxNorm normalized name: Vitamin E 4600 IU/5 ML Oral Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 IU of recombinant FSH plus daily supplementation with 75 IU of recombinant hCG (group C)
Trial: 11575982
Drug: Acetaminophen 1000
RxNorm normalized name: acetaminophen 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1000 mg, orally, 4 times daily for 2 days
Trial: 11575982
Drug: Placebo, orally,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, orally, 4 times daily for 2 days
Trial: 10230643
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy with metformin
Trial: 10230643
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy without metformin
Trial: 826960
Drug: Adrenaline injections
RxNorm normalized name: epinephrine Injection [Adrenalin]
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adrenaline injections
Trial: 26534874
Drug: 400μg buccal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400μg buccal misoprostol
Trial: 26534874
Drug: 800μg placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800μg placebo buccal
Trial: 20508907
Drug: Idraparinux (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idraparinux (2.5 mg, once-weekly subcutaneous injection)
Trial: 20508907
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (heparin followed by vitamin K antagonists)
Trial: 8142791
Drug: Self-directed treatment
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-directed treatment manual
Trial: 2131504
Drug: Essential amino
RxNorm normalized name: Essential amino acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential amino acids supplementation added to a protein restricted diet (0.6 g/kg/day)
Trial: 134723
Drug: ipratropiumbromide (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ipratropiumbromide (0.02 mg per puff, 3 x 2 puffs)
Trial: 25913498
Drug: SoluMatrix diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SoluMatrix diclofenac 35 mg b.i.d. (which could be increased to t.i.d. as needed)
Trial: 19207134
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (MgSO4) 10 mmol
Trial: 15109586
Drug: Pharmacological or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological or surgical treatment
Trial: 2587002
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (3 cycles)
Trial: 2587002
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy and surgery or radiotherapy
Trial: 29488475
Drug: Antihypertensive drugs
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive drugs and an anxiolytic (adaptol)
Trial: 23158073
Drug: Antihypertensive drugs
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive drugs only
Trial: 19308789
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg caffeine . kg(‐1) body mass (BM)
Trial: 19308789
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg caffeine . kg(‐1) BM
Trial: 20816042
Drug: Armodafinil 100
RxNorm normalized name: armodafinil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armodafinil 100 mg
Trial: 16393442
Drug: Armodafinil 300
RxNorm normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Armodafinil 300 mg
Trial: 9396910
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of dexamethasone in saline solution (study group, n = 50)
Trial: 9396910
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution only (control group, n = 48)
Trial: 29522941
Drug: Bupropion-SSRI combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion-SSRI combination
Trial: 27622558
Drug: Scheduled intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled intermittent screening with malaria rapid diagnostic tests and treatment with dihydroartemisinin-piperaquine (ISTp-DP)
Trial: 27622558
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive therapy with sulfadoxine-pyrimethamine (IPTp-SP)
Trial: 24755129
Drug: Ticagrelor 600
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 600 mg (SAD study)
Trial: 24755129
Drug: Ticagrelor 100
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 100 mg and 300 mg (MAD study)
Trial: 24755129
Drug: Ticagrelor >=
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor >= 100 mg (SAD study)
Trial: 20502014
Drug: Rivastigmine 17.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine 17.4 mg/24 h patch
Trial: 20502014
Drug: Rivastigmine 9.5
RxNorm normalized name: RIVASTIGMINE 9.5MG/24HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine 9.5 mg/24 h patch
Trial: 20502014
Drug: Rivastigmine patches
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine patches and capsules
Trial: 16042935
Drug: Topical 5-aminolevulinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5-aminolevulinic acid (ALA) and intense pulsed light (IPL)
Trial: 12443968
Drug: 1.0% C31G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0% C31G co-polymer gel
Trial: 12443968
Drug: 1.2% HEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2% HEC gel
Trial: 375850
Drug: Naproxen at
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen at 10 mg per kg body weight
Trial: 375850
Drug: Aspirin at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin at 80 mg per kg body weight
Trial: 28107821
Drug: Letrozole 20
RxNorm normalized name: ribociclib succinate/letrozole 200 mg/day (200 mg x 1)-2.5 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 20 mg administered when the dominant follicle reached 12 mm
Trial: 28107821
Drug: Letrozole 20
RxNorm normalized name: ribociclib succinate/letrozole 200 mg/day (200 mg x 1)-2.5 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 20 mg administered when the dominant follicle reached 18 mm
Trial: 28107821
Drug: Letrozole 20
RxNorm normalized name: ribociclib succinate/letrozole 200 mg/day (200 mg x 1)-2.5 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 20 mg administered on the first day following ovulation (post‐ovulation)
Trial: 28107821
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (treatment withheld)
Trial: 27186989
Drug: Metered dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered dose inhalers (MDIs) with spacers
Trial: 15979021
Drug: Venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine XR 150 mg
Trial: 8961722
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg dextroamphetamine (10 mg doses at midnight, 4 a.m., and 8 a.m.)
Trial: 1301641
Drug: Meperidine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine administered via femoral block
Trial: 1301641
Drug: Meperidine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine administered intravenously
Trial: 1301641
Drug: Meperidine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine administered via interscalene block
Trial: 3886301
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 mg) with chlorthalidone (12.5 mg)
Trial: 3886301
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 mg) alone
Trial: 3886301
Drug: Chlorthalidone (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (12.5 mg) alone
Trial: 16416000
Drug: Hugan tablets
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hugan tablets
Trial: 26382733
Drug: Epratuzumab 100
RxNorm normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epratuzumab 100 mg Q2W
Trial: 26382733
Drug: Epratuzumab 400
RxNorm normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epratuzumab 400 mg Q2W
Trial: 26382733
Drug: Epratuzumab 600
RxNorm normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epratuzumab 600 mg QW
Trial: 26382733
Drug: Epratuzumab 1200
RxNorm normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epratuzumab 1200 mg Q2W
Trial: 26382733
Drug: Epratuzumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epratuzumab (all doses)
Trial: 15681764
Drug: Oral insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral insulin (1 mg/day)
Trial: 15681764
Drug: Oral insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral insulin (10 mg/day)
Trial: 11120935
Drug: Thalidomide 100
RxNorm normalized name: thalidomide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide 100 mg orally, 3 times per week for 6 months
Trial: 9613081
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg of long-acting propranolol hydrochloride-betacap (Natko, India)
Trial: 7626966
Drug: Serotonin reuptake
RxNorm normalized name: Selective serotonin reuptake inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonin reuptake inhibitors (treatment duration: 10 to 12 weeks)
Trial: 1720479
Drug: Isradipine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (2.5 or 5 mg b.i.d.)
Trial: 1720479
Drug: Hydrochlorothiazide (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (12.5 or 25 mg b.i.d.)
Trial: 6184938
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment with dextran
Trial: 31138247
Drug: 5% albumin
RxNorm normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% albumin infusion (10 ml/kg) administered slowly (180 min)
Trial: 31138247
Drug: 5% albumin
RxNorm normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% albumin infusion (10 ml/kg) administered rapidly (30 min)
Trial: 22746358
Drug: Physiotherapist-guided pelvic
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapist-guided pelvic floor muscle training (PFMT) once weekly for 12 months (Group A, n=42)
Trial: 11422148
Drug: Oral montelukast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral montelukast (10 mg tablet for adults, 5 mg chewable tablet for children)
Trial: 11422148
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (beclomethasone 200 microg twice daily for adults, 100 microg or equivalent three times daily for children)
Trial: 9727891
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg troglitazone
Trial: 9727891
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg troglitazone
Trial: 31469243
Drug: Tocilizumab (TCZ)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (TCZ) 8mg/kg intravenous infusions
Trial: 31469243
Drug: Etanercept 50mg
RxNorm normalized name: ETANERCEPT 50MG/ML INJ SYRINGE
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept 50mg subcutaneous injections
Trial: 28634121
Drug: Tobramycin inhalation
RxNorm normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin inhalation solution (300 mg, twice daily)
Trial: 24301236
Drug: Abobotulinum toxin
RxNorm normalized name: tetanus toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abobotulinum toxin A (ABO) at doses ranging from 120 to 250 U
Trial: 24301236
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of ABO in the perioral area
Trial: 19584187
Drug: GH replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH replacement therapy (0.012 mg/kg every second day, approximately 2.5 IU)
Trial: 17582635
Drug: Slow-releasing drug-eluting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-releasing drug-eluting stents (sirolimus and paclitaxel)
Trial: 17582635
Drug: Rapid-releasing drug-eluting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid-releasing drug-eluting stents (sirolimus and paclitaxel)
Trial: 16260342
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol (0.4 mg)
Trial: 11394732
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bupropion SR and nicotine patch
Trial: 31509849
Drug: Needle penetration
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle penetration without injection (placebo)
Trial: 30912296
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea (GT) treatment for 4 months
Trial: 30912296
Drug: Hot water
RxNorm normalized name: hot water bottle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hot water (HW) ingestion for 4 months (after GT treatment in Grp1)
Trial: 30912296
Drug: Hot water
RxNorm normalized name: hot water bottle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hot water (HW) ingestion for 4 months (before GT treatment in Grp2)